Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GLUE
#1873
Monte Rosa Therapeutics, Inc. Common Stock
17.750
0
-1.99%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-1.99%
Monthly Change
-23.16%
6 month change
+57.08%
Year Change
+57.08%
Previous Close
18.110
0
Open
17.750
0
Bid
Ask
Low
17.750
0
High
17.750
0
Volume
104
Markets
US Stock Market
Healthcare
GLUE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
46.63 M
49.36 M
50.15 M
61.51 M
—
Valuation ratios
Enterprise value
606.12 M
329.1 M
158.28 M
202.62 M
892.79 M
Price to earnings ratio
—
-3.38
-2.17
-7.08
63.44
Price to sales ratio
—
-1 113.42
526.89
6.78
14.34
Price to cash flow ratio
—
3.97
6.7
12.21
7.12
Price to book ratio
—
1.35
1.64
2.3
3.65
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.32
0.45
0.17
0.18
Return on equity %
0.21
0.4
0.76
0.33
0.27
Return on invested capital %
1 643.95
344.9
265.4
178.75
190.77
Gross margin %
100
100
100
100
400
Operating margin %
40.72 K
-34.06 K
25.73 K
107.26
355.73
EBITDA margin %
—
—
—
—
—
Net margin %
41.32 K
-32.88 K
24.3 K
96.14
298.16
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
20.96
10.79
5.07
2.4
21.71
Inventory turnover
—
—
—
—
—
Asset turnover
0
-0
0
0.2
0.46
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1.96
0.85
0.57
-0.37
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
1.16
2.49
3.03
12.27
Net current asset value per share
—
5.84
4.6
5.11
17.63
Tangible book value per share
—
5.75
3.49
3.02
12.58
Working capital per share
—
5.3
3.69
2.98
13.54
Book value per share
—
5.75
3.49
3.02
12.58
News
Monte Rosa shares rise on prostate cancer trial results
Monte Rosa reports positive trial data for prostate cancer drug
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler
Monte Rosa Therapeutics prices $300 million public offering
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
Monte Rosa Therapeutics launches $200 million public offering
Monte Rosa stock rises as TD Cowen reiterates Buy rating on NEK7 degrader data
Monte Rosa stock price target raised to $31 by Jefferies on NEK7 degrader data
Eli Lilly and Regencell among market cap stock movers on Wednesday
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why